Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Letrozole in ER+ Relapsed Ovarian and Endometrial Cancers
NCT02657928Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2016
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC) and 1 more, sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 12 Weeks. Started Jul 2016; status: completed.
02
Drugs
ribociclib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02657928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657928.